Randomized phase 2 trial of NP001–a novel immune regulator: Safety and early efficacy in ALS

OBJECTIVE: To assess the safety, tolerability, and preliminary efficacy of NP001, a novel immune regulator of inflammatory monocytes/macrophages, for slowing progression of amyotrophic lateral sclerosis (ALS). METHODS: This was a phase 2 randomized, double-blind, placebo-controlled trial of NP001 in...

Descripción completa

Detalles Bibliográficos
Autores principales: Miller, Robert G., Block, Gilbert, Katz, Jonathan S., Barohn, Richard J., Gopalakrishnan, Vidhya, Cudkowicz, Merit, Zhang, Jane R., McGrath, Michael S., Ludington, Elizabeth, Appel, Stan H., Azhir, Ari
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4396529/
https://www.ncbi.nlm.nih.gov/pubmed/25884010
http://dx.doi.org/10.1212/NXI.0000000000000100

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4396529/
https://www.ncbi.nlm.nih.gov/pubmed/25884010
http://dx.doi.org/10.1212/NXI.0000000000000100

Ejemplares similares